Ocrelizumab is dampening the harm inflammation in patients with multiple sclerosis with little impact on protective immunity
-
Published:2020-06-18
Issue:3
Volume:21
Page:214-220
-
ISSN:1213-1814
-
Container-title:Neurologie pro praxi
-
language:
-
Short-container-title:Neurol. pro Praxi